Semaglutide, a novel glucagon-like peptide-1 agonist, amends experimental autoimmune encephalomyelitis-induced multiple sclerosis in mice: Involvement of the PI3K/Akt/GSK-3β pathway
Mohamed A. Sadek, Esraa A. Kandil, Nesrine S. El Sayed, Helmy M. Sayed, Mostafa A. Rabie
Topics & Concepts
Experimental autoimmune encephalomyelitisSemaglutideNeuroprotectionRemyelinationMedicineAgonistMultiple sclerosisPI3K/AKT/mTOR pathwayNeuroinflammationCentral nervous systemNeurosciencePharmacologyImmunologyEndocrinologyInternal medicineReceptorLiraglutideBiologyInflammationSignal transductionDiabetes mellitusType 2 diabetesMyelinCell biologyNF-κB Signaling PathwaysNatural product bioactivities and synthesisChronic Lymphocytic Leukemia Research